PortfoliosLab logoPortfoliosLab logo
CRVS vs. URA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CRVS vs. URA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corvus Pharmaceuticals, Inc. (CRVS) and Global X Uranium ETF (URA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRVS achieves a 54.94% return, which is significantly higher than URA's 6.53% return. Over the past 10 years, CRVS has underperformed URA with an annualized return of 0.06%, while URA has yielded a comparatively higher 15.90% annualized return.


CRVS

1D
2.84%
1M
-24.68%
YTD
54.94%
6M
42.53%
1Y
181.37%
3Y*
53.32%
5Y*
33.63%
10Y*
0.06%

URA

1D
1.54%
1M
-14.61%
YTD
6.53%
6M
3.57%
1Y
32.44%
3Y*
32.17%
5Y*
18.77%
10Y*
15.90%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CRVS vs. URA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRVS
Corvus Pharmaceuticals, Inc.
54.94%43.93%203.98%107.06%-64.73%-32.30%-34.56%48.23%-64.58%-27.55%
URA
Global X Uranium ETF
6.53%67.18%-0.58%46.25%-11.32%57.57%41.33%-3.54%-22.11%19.36%

Correlation

The correlation between CRVS and URA is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.25

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Mar 23, 2016

0.22

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRVS vs. URA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRVS
CRVS Risk / Return Rank: 8686
Overall Rank
CRVS Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
CRVS Sortino Ratio Rank: 9696
Sortino Ratio Rank
CRVS Omega Ratio Rank: 9393
Omega Ratio Rank
CRVS Calmar Ratio Rank: 8585
Calmar Ratio Rank
CRVS Martin Ratio Rank: 8383
Martin Ratio Rank

URA
URA Risk / Return Rank: 2323
Overall Rank
URA Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
URA Sortino Ratio Rank: 2424
Sortino Ratio Rank
URA Omega Ratio Rank: 2323
Omega Ratio Rank
URA Calmar Ratio Rank: 2525
Calmar Ratio Rank
URA Martin Ratio Rank: 2121
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRVS vs. URA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and Global X Uranium ETF (URA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CRVSURADifference
Sharpe ratioReturn per unit of total volatility

+0.38

Sortino ratioReturn per unit of downside risk

+3.04

Omega ratioGain probability vs. loss probability

1.48

1.14

+0.34

Calmar ratioReturn relative to maximum drawdown

3.23

1.04

+2.20

Martin ratioReturn relative to average drawdown

7.03

2.30

+4.73

CRVS vs. URA - Sharpe Ratio Comparison

The current CRVS Sharpe Ratio is 1.01, which is higher than the URA Sharpe Ratio of 0.64. The chart below compares the historical Sharpe Ratios of CRVS and URA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CRVS vs. URA - Drawdown Comparison

The maximum CRVS drawdown since its inception was -96.97%, roughly equal to the maximum URA drawdown of -93.54%. Use the drawdown chart below to compare losses from any high point for CRVS and URA.


Loading charts...

Drawdown Indicators


CRVSURADifference

Max Drawdown

Largest peak-to-trough decline

-96.97%

-93.54%

-3.43%

Max Drawdown (1Y)

Largest decline over 1 year

-56.43%

-31.48%

-24.95%

Max Drawdown (3Y)

Largest decline over 3 years

-70.50%

-37.81%

-32.69%

Max Drawdown (5Y)

Largest decline over 5 years

-92.40%

-37.90%

-54.50%

Max Drawdown (10Y)

Largest decline over 10 years

-96.97%

-61.45%

-35.52%

Current Drawdown

Current decline from peak

-53.25%

-48.34%

-4.91%

Average Drawdown

Average peak-to-trough decline

-69.28%

-74.94%

+5.66%

Ulcer Index

Depth and duration of drawdowns from previous peaks

25.91%

14.12%

+11.79%

Volatility

CRVS vs. URA - Volatility Comparison

Corvus Pharmaceuticals, Inc. (CRVS) has a higher volatility of 23.12% compared to Global X Uranium ETF (URA) at 17.69%. This indicates that CRVS's price experiences larger fluctuations and is considered to be riskier than URA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRVSURADifference

Volatility (1M)

Calculated over the trailing 1-month period

23.12%

17.69%

+5.43%

Volatility (6M)

Calculated over the trailing 6-month period

111.88%

39.95%

+71.93%

Volatility (1Y)

Calculated over the trailing 1-year period

180.64%

51.24%

+129.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

131.02%

43.96%

+87.06%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

111.13%

37.91%

+73.22%

Dividends

CRVS vs. URA - Dividend Comparison

CRVS has not paid dividends to shareholders, while URA's dividend yield for the trailing twelve months is around 4.58%.


PositionTTM20252024202320222021202020192018201720162015
CRVS
Corvus Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
URA
Global X Uranium ETF
4.58%4.88%2.86%6.07%0.76%5.84%1.69%1.66%0.44%2.03%7.28%1.96%

Frequently Asked Questions


CRVS and URA have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRVS has higher volatility (23.12%) compared to URA (17.69%). In terms of maximum drawdown, CRVS dropped -96.97% vs URA's -93.54%.

CRVS currently has the higher Sharpe Ratio (1.01 vs 0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRVS and URA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer